Poor prognosis of constitutive gamma-H2AX expressing triple-negative breast cancers is associated with telomere length
Publication year
2015Source
Biomarkers in Medicine, 9, 4, (2015), pp. 383-90ISSN
Publication type
Article / Letter to editor
Display more detailsDisplay less details
Organization
Radiation Oncology
Laboratory Medicine
Human Genetics
Journal title
Biomarkers in Medicine
Volume
vol. 9
Issue
iss. 4
Page start
p. 383
Page end
p. 90
Subject
Radboudumc 14: Tumours of the digestive tract RIMLS: Radboud Institute for Molecular Life Sciences; Radboudumc 17: Women's cancers RIHS: Radboud Institute for Health Sciences; Radboudumc 9: Rare cancers RIHS: Radboud Institute for Health SciencesAbstract
AIM: Here, we set out to establish whether endogenous gamma-H2AX is a biomarker in triple-negative breast cancer. METHODS: We explored the association of gamma-H2AX with mutation status and sensitivity to 139 different anticancer drugs in up to 41 breast cancer cell lines. Further, we correlated gamma-H2AX expression in breast cancer tumor tissues with telomere length. RESULTS: gamma-H2AX positive breast cancer cells exhibit more mutations, and - when p53 mutated - have shorter telomeres. In breast cancer patients gamma-H2AX is also related to shorter telomeres, which was in turn associated with poorer prognosis of triple-negative breast cancer patients. CONCLUSION: Thus, endogenous gamma-H2AX is associated with short telomeres, which might offer a specific target for therapy for triple-negative breast cancer patients.
This item appears in the following Collection(s)
- Academic publications [245054]
- Faculty of Medical Sciences [93209]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.